EUCTR2018-001069-18-IT
Active, not recruiting
Phase 1
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab inCombination with Chemotherapy as First-Line Treatment in Patients withGastric or Gastroesophageal Junction Adenocarcinoma - ooo
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO
- Enrollment
- 420
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Eastern Cooperative Oncology Group (ECOG) performance status score
- •\- Histologically\- or cytologically\-confirmed diagnosis of unresectable,
- •locally advanced, or metastatic gastric cancer or GEJ adenocarcinoma
- •\- No prior treatment with systemic treatment (including HER 2
- •inhibitors) given as primary therapy for unresectable, locally advanced,
- •or metastatic GC or GEJ adenocarcinoma
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 294
Exclusion Criteria
- •\- Participants with HER2 positive status
- •\- Participants with known untreated central nervous system (CNS)
- •\- Uncontrolled or significant cardiovascular disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001069-18-ATBristol-Myers Squibb International Corporation420
Active, not recruiting
Phase 1
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001069-18-NOBristol-Myers Squibb International Corporation420
Active, not recruiting
Phase 1
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersEUCTR2018-001069-18-DEBristol-Myers Squibb International Corporation420
Active, not recruiting
Phase 1
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001069-18-BEBristol-Myers Squibb International Corporation420
Active, not recruiting
Phase 1
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersEUCTR2018-001069-18-CZBristol-Myers Squibb International Corporation420